Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this Antibody Drug Conjugates Market (5th Edition), 2019-2030.
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Antibody Drug Conjugates Market (5th Edition), 2019-2030.er
3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Antibody Drug Conjugates Market (5th Edition), 2019-2030.er
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
4.3. ADC Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Number of ADC Therapeutics
4.4. ADC Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Size and Target Indication
4.5. Novel Drug Conjugates
5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and Future Outlook
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and Future Outlook
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximab soravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and Future Outlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and Future Outlook
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin
5.8.3.2
- Get latest and updated exam material from mockdumps with passing guarantee in first try. We provide 24/7 customer support to our honorable students
- 100% real and updated exam questions with answers for all famous certifications. Pass in first attempt .Error Free Products with 24/7 Customer Support.Special discount offer for all customer
- In addition to seniors over age of 65, appointments are also available to long-term facility staff and health care workers at certain locations in Miami.
- Boris Johnson is preparing to outline the tests the government will use to determine whether foreign travel